Eva
Pérez Pampín
Hospital Miguel Servet
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Miguel Servet (7)
2020
-
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice
Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119
2019
-
Objectives and methodology of BIOBADASER phase III
Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236
-
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 1, pp. 126-135
2015
-
Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain
Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640
2011
-
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
Rheumatology, Vol. 50, Núm. 1, pp. 85-92
2010
-
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755
2008
-
Reacciones adversas relacionadas con la administración de inhibidores del TNF. Análisis de un registro de terapias biológicas
Reumatologia Clinica, Vol. 4, Núm. 3, pp. 90-95